278 related articles for article (PubMed ID: 14761193)
1. Effects of C2-alkylation, N-alkylation, and N,N'-dialkylation on the stability and estrogen receptor interaction of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
von Rauch M; Schlenk M; Gust R
J Med Chem; 2004 Feb; 47(4):915-27. PubMed ID: 14761193
[TBL] [Abstract][Full Text] [Related]
2. Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
von Rauch M; Busch S; Gust R
J Med Chem; 2005 Jan; 48(2):466-74. PubMed ID: 15658860
[TBL] [Abstract][Full Text] [Related]
3. (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: ligands for the estrogen receptor with a novel binding mode.
Gust R; Keilitz R; Schmidt K; von Rauch M
J Med Chem; 2002 Aug; 45(16):3356-65. PubMed ID: 12139447
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, structural evaluation, and estrogen receptor interaction of 4,5-bis(4-hydroxyphenyl)imidazoles.
Gust R; Keilitz R; Schmidt K; von Rauch M
Arch Pharm (Weinheim); 2002 Dec; 335(10):463-71. PubMed ID: 12506394
[TBL] [Abstract][Full Text] [Related]
5. Invesgations [correction investigations] on the influence of halide substituents on the estrogen receptor interaction of 2, 4, 5-tris(4-hydroxyphenyl)imidazoles.
Gust R; Busch S; Keilitz R; Schmidt K; Von Rauch M
Arch Pharm (Weinheim); 2003 Oct; 336(10):456-65. PubMed ID: 14582122
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Lubczyk V; Bachmann H; Gust R
J Med Chem; 2003 Apr; 46(8):1484-91. PubMed ID: 12672249
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diarylpiperazines.
Gust R; Keilitz R; Schmidt K
J Med Chem; 2002 May; 45(11):2325-37. PubMed ID: 12014971
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1H-imidazoles.
Wiglenda T; Gust R
J Med Chem; 2007 Apr; 50(7):1475-84. PubMed ID: 17352461
[TBL] [Abstract][Full Text] [Related]
9. Cobalt-alkyne complexes with imidazoline ligands as estrogenic carriers: synthesis and pharmacological investigations.
Schlenk M; Ott I; Gust R
J Med Chem; 2008 Nov; 51(22):7318-22. PubMed ID: 18942824
[TBL] [Abstract][Full Text] [Related]
10. Investigations of new lead structures for the design of selective estrogen receptor modulators.
Gust R; Keilitz R; Schmidt K
J Med Chem; 2001 Jun; 44(12):1963-70. PubMed ID: 11384241
[TBL] [Abstract][Full Text] [Related]
11. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
Gust R; Niebler K; Schönenberger H
J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
[TBL] [Abstract][Full Text] [Related]
12. Effects of (R,S)/(S,R)-4,5-bis(2-chloro-4-hydroxyphenyl)-2-imidazolines and (R,S)/(S,R)-2,3-bis(2-chloro-4-hydroxyphenyl)piperazines on estrogen receptor alpha level and transcriptional activity in MCF-7 cells.
Laïos I; Cleeren A; Leclercq G; Nonclercq D; Laurent G; Schlenk M; Wellner A; Gust R
Biochem Pharmacol; 2007 Oct; 74(7):1029-38. PubMed ID: 17706611
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacological evaluation of 1H-imidazoles as ligands for the estrogen receptor and cytotoxic inhibitors of the cyclooxygenase.
Wiglenda T; Ott I; Kircher B; Schumacher P; Schuster D; Langer T; Gust R
J Med Chem; 2005 Oct; 48(20):6516-21. PubMed ID: 16190777
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells.
Jacquot Y; Laïos I; Cleeren A; Nonclercq D; Bermont L; Refouvelet B; Boubekeur K; Xicluna A; Leclercq G; Laurent G
Bioorg Med Chem; 2007 Mar; 15(6):2269-82. PubMed ID: 17275315
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of p-carborane bisphenols and their derivatives: structure-activity relationship for estrogenic activity.
Ogawa T; Ohta K; Iijima T; Suzuki T; Ohta S; Endo Y
Bioorg Med Chem; 2009 Feb; 17(3):1109-17. PubMed ID: 19141368
[TBL] [Abstract][Full Text] [Related]
16. Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
Lubczyk V; Bachmann H; Gust R
J Med Chem; 2002 Nov; 45(24):5358-64. PubMed ID: 12431063
[TBL] [Abstract][Full Text] [Related]
17. 2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor alpha.
Zimmermann J; Liebl R; von Angerer E
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):57-66. PubMed ID: 15862950
[TBL] [Abstract][Full Text] [Related]
18. Structure activity relationship studies on C2 side chain substituted 1,1-bis(4-methoxyphenyl)-2-phenylalkenes and 1,1,2-tris(4-methoxyphenyl)alkenes.
Gust R; Lubczyk V
J Steroid Biochem Mol Biol; 2003 Oct; 87(1):75-83. PubMed ID: 14630093
[TBL] [Abstract][Full Text] [Related]
19. Investigations on the influence of terminal groups at the C2-propyl side chain of 1,1-bis(4-hydroxyphenyl)-2-phenylpent-1-ene and 1,1,2-tris(4-hydroxyphenyl)pent-1-ene on the estrogen receptor binding and the estrogenic/anti-estrogenic properties.
Gust R; Lubczyk V
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):57-70. PubMed ID: 12943745
[TBL] [Abstract][Full Text] [Related]
20. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
